Annals of Surgical Oncology

, Volume 24, Issue 11, pp 3345–3352 | Cite as

Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis

  • Hironori Yamaguchi
  • Yumiko Satoh
  • Hironori Ishigami
  • Makiko Kurihara
  • Yutaka Yatomi
  • Joji Kitayama
Gastrointestinal Oncology
  • 305 Downloads

Abstract

Background

The outcome of gastric cancer patients with peritoneal metastasis remains poor. We treated these patients with intraperitoneal and intravenous paclitaxel plus oral S-1 (tegafur/gimeracil/oteracil), followed by gastrectomy in responders. We evaluated the clinical significance of peritoneal lavage carcinoembryonic antigen (CEA) messenger RNA (mRNA) levels as a biomarker for indication of conversion gastrectomy.

Methods

The peritoneal lavage of 68 patients who received the above regimen as induction chemotherapy was repeatedly collected via intraperitoneal access ports. Gastrectomy was considered when improvement of peritoneal metastasis was confirmed by a second laparoscopic examination with negative peritoneal cytology. CEA and porphobilinogen deaminase mRNAs were chronologically quantified using the transcription reverse-transcription concerted reaction method. The CEA mRNA index (CmRI) was calculated as CEA mRNA/porphobilinogen deaminase mRNA × 10,000.

Results

Thirty-nine patients underwent gastrectomy and 29 patients did not (median survival time, 27.8 vs. 10.7 months, respectively; P < 0.001). In gastrectomy-positive patients, the outcome largely differed according to CmRI values immediately prior to surgery. Patients with a preoperative CmRI value <100 (n = 20) were associated with a significantly longer survival than those with a preoperative CmRI value >100 (n = 19) (41.8 vs. 20.1 months, respectively; P < 0.001). A preoperative CmRI value <100 was confirmed as an independent predictor of survival for gastrectomy-positive patients in the multivariate analysis.

Conclusions

The CmRI reflects the response of peritoneal metastases to induction intraperitoneal chemotherapy. It may be a useful biomarker for indicating gastrectomy in gastric cancer patients with peritoneal metastasis.

Notes

Disclosure

The authors have nothing to disclose.

Funding

This research was partially funded by a Grant from the Japan Agency for Medical Research and Development, and a KAKENHI Grant-in-Aid for Scientific Research (No. 15K10086) from the Japan Society for the Promotion of Science.

Supplementary material

10434_2017_5997_MOESM1_ESM.tiff (5.9 mb)
Supplementary material 1 (TIFF 6079 kb) Alterations in carcinoembryonic antigen (CEA) messenger RNA (mRNA) index values during induction chemotherapy in conversion gastrectomy patients with a preoperative CEA mRNA index value of (a) <100 (n = 20) or (b) >100 (n = 19). The x-axis represents the number of days since commencing induction chemotherapy. c Alterations in CEA mRNA index values during first-line chemotherapy up until the point of switching to second-line treatment in patients who did not undergo conversion gastrectomy (n = 29)

References

  1. 1.
    Yamao T, Shimada Y, Shirao K, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004;34:316–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Imazawa M, Kojima T, Boku N, et al. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer. 2009;12:153–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Oh SY, Kwon HC, Lee S, et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol. 2007;37:930–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Kitayama J, Ishigami H, Yamaguchi H, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol. 2014;21:539–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Yamaguchi H, Kitayama J, Ishigami H, et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: intraperitoneal chemotherapy with taxanes. World J Gastrointest Oncol. 2015;7:285–91.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Fushida S, Kinoshita J, Kaji M, et al. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265–72.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105:38–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Ishigami H, Kitayama J, Otani K, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76:311–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20:128–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Ishii T, Fujiwara Y, Ohnaka S, et al. Rapid genetic diagnosis with the transcription-reverse transcription concerted reaction system for cancer micrometastasis. Ann Surg Oncol. 2004;11:778–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Murono K, Kazama S, Yamaguchi H, et al. Detection of carcinoembryonic antigen mRNA in peritoneal lavage by the transcription-reverse transcription concerted method indicates poor prognosis in patients with stage II and III colon cancer. Surgery. 2015;157:322–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Kodera Y, Nakanishi H, Ito S, et al. Quantitative detection of disseminated cancer cells in the greater omentum of gastric carcinoma patients with real-time RT-PCR: a comparison with peritoneal lavage cytology. Gastric Cancer. 2002;5:69–76.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang JY, Lin SR, Lu CY, et al. Gastric cancer cell detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen transcripts versus the combined cytology with peritoneal carcinoembryonic antigen levels. Cancer Lett. 2005;223:129–35.CrossRefPubMedGoogle Scholar
  16. 16.
    Fujiwara Y, Doki Y, Taniguchi H, et al. Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives. Gastric Cancer. 2007;10:197–204.CrossRefPubMedGoogle Scholar
  17. 17.
    Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Takata A, Kurokawa Y, Fujiwara Y, et al. Prognostic value of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer. World J Surg. 2014;38:1107–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Li Z, Zhang D, Zhang H, Miao Z, Tang Y, Sun G, Dai D. Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients. Tumour Biol. 2014;35:3463–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Horikawa M, Iinuma H, Inoue T, Ogawa E, Fukushima R. Clinical significance of intraperitoneal CD44 mRNA levels of magnetically separated CD45-negative EpCAM-positive cells for peritoneal recurrence and prognosis in stage II and III gastric cancer patients. Oncol Rep. 2011;25:1413–20.PubMedGoogle Scholar
  21. 21.
    Okada K, Fujiwara Y, Nakamura Y, et al. Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol. 2012;105:780–5.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Hironori Yamaguchi
    • 1
    • 2
  • Yumiko Satoh
    • 3
  • Hironori Ishigami
    • 4
  • Makiko Kurihara
    • 3
  • Yutaka Yatomi
    • 3
  • Joji Kitayama
    • 2
    • 5
  1. 1.Department of Clinical OncologyJichi Medical UniversityTochigiJapan
  2. 2.Department of Gastrointestinal SurgeryJichi Medical UniversityTochigiJapan
  3. 3.Department of Clinical LaboratoryThe University of Tokyo HospitalTokyoJapan
  4. 4.Department of ChemotherapyThe University of Tokyo HospitalTokyoJapan
  5. 5.Clinical Research Support CenterJichi Medical UniversityTochigiJapan

Personalised recommendations